p53 status of newly established acute myeloid leukaemia cell lines

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 407-415

  Zheng, A ^a   Castren, K ^a   Saily M ^a   Savolainen, E R ^a   Koistinen, P ^a   Vahakangas K ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

AML; Cell lines; p53

Indexed keywords

PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CELL NUCLEUS; CLINICAL ARTICLE; CYTOPLASM; EXON; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0032928791     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690064     Document Type: Article

References (60)

1. Bargonetti J, Friedman PN, Kern SE, Vogelstein B and Prives C (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton OAG, Gralnick HD and Sultan C (1976) Proposals for the classification of acute leukemias. Br J Haematol 33: 451-458
3. Bi S, Lanza F and Goldman JM (1994) The involvement of tumor suppressor p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 54: 582-586
4. Castren K, Vähäkangas K, Heikkinen E and Ranki A (1998) Absence of p53 mutations in benign and premalignant male genital lesions with overexpressed p53 protein. Int J Cancer 77: 674-678
5. Chowdary DR, Dermody JJ, Jha KK and Ozer HL (1994) Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14: 1997-2003
6. Chresta CM, Masters JRW and Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 56: 1834-1841
7. Dive C (1997) Avoidance of apoptosis as a mechanism of drug resistance. J Intern Med 242 (suppl. 740): 139-145
8. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabol G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Postka A, Hunstein W and Lichter P (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589
9. Elonen E for the Finnish Leukemia Group (1993) Intensive chemotherapy of adult acute myelogenous leukemia: a randomized trial between 4 and 8 cycles. Blood 82 (suppl. I): 328a
10. Fenaux P, Preudhomme C, Quiquandron I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R and Kerckaert JP (1992) Mutations of the p53 gene in acute myeloid leukemia. Br J Haematol 80: 178-183
11. Fritsche M, Haessler C and Brandner G (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318
12. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB and Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291
13. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871
14. Gannon JV, Greaves R, Iggo R and Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602
15. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1285: 77-102
16. Greenblatt MS, Bennet WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
17. Hainaut P (1995) The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Op Oncol 7: 76-82
18. Hainaut P and Vähäkangas K (1997) p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol 45: 833-844
19. Hall PA and Lane DP (1994) p53 in tumor pathology: can we trust immunohistochemistry? - revisited! J Pathol 172: 1-4
20. Hamblin TJ (1995) Disappointments in treating acute leukemia in the elderly. N Engl J Med 332: 1712-1713
21. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455
22. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hoving E, Smith-Sorensen B, Montesano R and Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551-3555
23. Imamura J, Miyoushi I and Koefller P (1994) p53 in hematological malignancies. Blood 84: 2412-2421
24. Isobe M, Emanuel B, Gival D, Oren M and Croce C (1986) Localization of gene for human p53 tumor antigen to band 17p13. Nature 320: 84-87
25. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
26. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054-1072
27. Kubbutat MHG and Vousden KH (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17: 460-468
28. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, Gerwin BI and Harris CC (1991) p53 mutations, ras mutations, and p53 heal shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090-4096
29. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
30. Linzer DI and Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52
31. Lowe SW, Ruley HE, Jacks T and Houseman DE (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer cells. Cell 74: 957-968
32. Lu X and Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing irradiation: defects in chromosome instability syndromes? Cell 75: 765-778
33. Lutzker S and Levine AJ (1996) A functionally inactive p53 protein in embryonal carcinoma cells is activated by DNA damage or cellular differentiation. Nature Med 2: 804-810
34. Maki CG and Howley PM (1997) Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17: 355-363
35. Maki CG, Huibregtse JM and Howley PM (1996) In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56: 2649-2654
36. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I and Haines DS (1996) High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 87: 1155-1161
37. Mcbride OW, Merry D and Givol D (1986) The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83: 130-134
38. Milner J (1994) Forms and functions of p53. Semin Cancer Biol 5: 211-219
39. Milner J and Medcalf EA (1991) Co-translation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774
40. Moll OM, Ostermeyer AG, Halady R, Winkfield B, Frazier M and Zambetti G (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the GI checkpoint after DNA damage. Mol Cell Biol 16: 1126-1137
41. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69: 1237-1245
42. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J and Gross PE (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53: 3574-3578
43. Rämet M, Castren K, Järvinen K, Pekkala K, Tupeennicmi-Hujanen T, Soini Y, Pääkkö P and Vähäkangas K (1995) p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16: 2117-2124
44. Rämet M, Turunen S, Pääkkö P, Laatio L, Raunio H, Hainaut P and Vähäkangas K (1998) Benzo(a)pyrene induces p53 and apoptosis but no G1 arrest in MCF-7 cells. (submitted)
45. Rivas CI, Wisniewski D, Strife A, Perez A, Lambek C, Bruno S, Darzynkiewicz Z and Clarkson B (1992) Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood 79: 1982-1986
46. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han C-i, Martin FD, Yen N, Xu K, Stephens LC, McDonnel TJ, Mukhopadhyay T and Cai D (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2: 985-991
47. Schottelius A, Brennscheidt U, Ludwig W-D, Mertelsmann RH, Herrmann F and Lübbert M (1994) Mechanisms of p53 alteration in acute leukemias. Leukemia 8; 1673-1681
48. Selivanova G and Wiman KG (1995) p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 66: 143-180
49. Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nuorva K, Pääkkö P and Vähäkangas K (1993) p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 68: 1029-1035
50. Steegenga WT, van der Eb AJ and Jochemsen AG (1996) How phosphorylation regulates the activity of p53. J Mol Biol 263: 103-113
51. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y and Hirai M (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79: 2378-2383
52. Symonds H, Krall L, Remington L, Saenz-Robies M, Lowe S, Jacks T and Van Dyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711
53. Tishler RB, Calderwood SK, Coleman N and Price BD (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216
54. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP and Harris CC (1992) Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576-580
55. Wada M, Asada M, Nakazawa S, Itoh H, Kobayashi Y, Inoue T, Fukumoro K, Chan L, Sugita K, Hanada R, Akuta N, Kobayashi N and Mizutani S (1994) Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8: 53-59
56. Welsh JA, Castren K and Vähäkangas K (1997) Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls. Clin Chem 43: 2251-2255
57. Zhang W, Hu G, Estey E, Hester J and Deisseroth A (1992) Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7: 1645-1647
58. Zhang W, Lu Q, Xie Z-J and Mellgren RL (1997) Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-leu-leu-tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for GI to S-phase transition. Oncogene 14: 255-263
59. Zhu Y-M, Bradbury D and Russell N (1993) Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer 68: 851-855
60. Zhu Y-M, Bradbury D and Russell N (1994) Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69: 468-47